Oral Bacterial Extract for the Prevention of Wheezing Lower Respiratory Tract Illness
Status:
Active, not recruiting
Trial end date:
2025-12-31
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to evaluate if Broncho-Vaxom® given to high risk
infants for 10 days, monthly, for two consecutive years can increase time to occurrence of
the first episode of wheezing lower respiratory tract illness (WLRI) during a three year
observation period off therapy.